Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14007246 | 1.00 | TAS1R3 (0.63) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL14007238 | 0.94 | TAS1R3 (0.54) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL4919682 | 0.87 | TAS1R3 (0.60) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL4928246 | 0.87 | TAS1R3 (0.60) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL5000133 | 0.81 | TAS1R3 (0.60) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL4929201 | 0.80 | TAS1R3 (0.51) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL4201276 | 0.78 | TAS1R3 (1.00) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL5000368 | 0.75 | AKT3 (0.54) | TAS1R3TAS1R1CNR1CNR2 | |
| SCHEMBL7990888 | 0.71 | CNR1 (0.60) | TAS1R3TAS1R1CNR1CNR2TAS1R2 | |
| SCHEMBL10527008 | 0.71 | HTT (0.80) | TAS1R3TAS1R1TAS1R2HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | CYP11B2, CYP11B1, REN | TAS1R3 3465/4885TAS1R1 3059/4885CNR1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.